查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2010053

镇痛药市场：2026-2032年全球市场预测（依药物类型、给药途径、适应症及通路划分）

Analgesics Market by Type of Drug, Route of Administration, Indication, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年止痛药市值为449.6亿美元，预计2026年将成长至479.9亿美元，复合年增长率为7.04%，到2032年将达到724.3亿美元。

主要市场统计数据
基准年 2025 449.6亿美元
预计年份：2026年 479.9亿美元
预测年份 2032 724.3亿美元
复合年增长率 (%) 7.04%

对不断发展的镇痛生态系统进行简要概述，重点关注影响临床需求、监管压力和相关人员策略的创新驱动因素。

目前镇痛药的发展现况正处于临床需求、监管和治疗方法快速进步的交会点。患者和临床医生都渴望获得有效、安全且易于获得的急性和慢性疼痛管理方案，而製药公司则面临着阿片类药物管控、製剂创新和供应链韧性方面的严峻挑战。在此背景下，公共的讨论和新型给药技术的出现正在重塑镇痛药的研发、分销和应用方式。

展望未来，概述临床、技术和监管方面的变化，这些变化正在重新定义研发路径、处方行为和分销策略。

镇痛领域正经历着一场变革性的转变，这场变革是由临床、技术和政策因素共同推动的。在临床上，对多方面疼痛管理的日益重视提升了非阿片类药物疗法和辅助治疗策略的重要性，从而减少了对高剂量阿片类药物处方的依赖，同时为开发针对特定疼痛类型的差异化製剂创造了机会。药物科学领域的技术进步，例如缓释基质和经皮给药平台，正在拓展治疗选择，并实现更精准的给药方案。

透过证据分析，探讨美国在 2025 年前的关税措施将如何重塑整个止痛药价值链的供应链、筹资策略和业务永续营运。

贸易政策决策的累积影响，包括美国计画在2025年前实施的关税措施，正为止痛药供应链和製造业经济带来新的复杂性。影响原材料、活性药物成分和成品的关税措施可能会增加依赖全球供应商网路的製造商和契约製造製造商的采购成本。为此，各公司正在重新审视其筹资策略，寻求将某些投入品近岸外包，并协商签订长期供应商合同，以稳定投入成本并最大限度地减少生产中断。

从详细的细分观点，将药物类别、给药途径、临床适应症和通路联繫起来，以指导产品设计和渠道策略。

市场区隔洞察揭示了临床需求与商业性机会的交汇点，对产品、给药途径、适应症和分销动态的详细分析有助于明确创新和投资重点。根据药物类型，市场分为非鸦片类药物和鸦片类药物。非鸦片类药物包括对乙酰胺酚、非类固醇消炎剂和水杨酸盐，而鸦片类药物则进一步细分为可待因、Fentanyl、氢可酮、氢可酮和羟考酮，每种药物都有其独特的临床应用特征和监管考虑。根据给药途径，可选择肌肉注射、静脉注射、口服、直肠给药、局部用药和经皮给药，其中口服剂型又分为胶囊和锭剂。每种给药途径都面临不同的製剂挑战和病患依从性问题。

对美洲、欧洲、中东和非洲以及亚太地区的监管多样性、支付方优先事项和分销复杂性进行区域评估，这些因素会影响准入和分销。

区域趋势影响需求模式、监管预期和分销重点，对美洲、欧洲、中东和非洲以及亚太地区的影响各不相同。在美洲，医疗保健系统和支付方结构优先考虑急性护理和门诊慢性疼痛管理的效率，尤其重视阿片类药物的管理，这影响着处方行为和药物在处方药清单中的纳入。美洲的监管和报销环境通常鼓励开展以真实临床实践中的疗效和安全性为重点的证据研究，这影响着临床应用和采购决策。

竞争分析强调，基于证据的差异化、策略伙伴关係和供应链敏捷性是镇痛领域长期成功的决定因素。

镇痛药市场的竞争格局由成熟的製药公司、专业生产商和专注于製剂和给药技术的创新新兴企业组成。市场领导者往往凭藉临床证据、安全性以及供应链可靠性展开竞争，而新参与企业则透过创新的给药平台、滥用预防功能和针对性适应症策略脱颖而出。生物製药公司与技术提供者之间的合作日益普遍，从而能够整合数位健康元素，以支持药物依从性和真实世界数据（REW）的收集。

为高阶主管提供可操作的建议，以协调产品创新、供应链韧性、证据生成和伙伴关係与不断变化的临床和监管重点。

产业领导企业应优先采取策略措施，使产品开发与临床实务、监管要求以及具有韧性的供应链设计相契合，以保持竞争优势。首先，投资于防滥用功能和以病人为中心的配方，既能满足临床需求，又能符合监管要求。专注于开发既能降低滥用风险又能维持镇痛效果的给药系统，将赢得处方医生和保险公司的支持。其次，透过供应商多元化、关键原材料近岸采购以及提高库存透明度来增强供应链韧性，可以降低贸易政策波动和意外中断带来的风险。

透明且有系统的研究途径，结合专家访谈、文献整合和迭代检验，为可靠的见解奠定了基础，这些见解可以立即用于决策。

本研究采用多面向方法，结合一手质性访谈、二手文献整合和结构化资料检验，以确保获得可靠且可操作的见解。一手研究包括对临床医生、处方集管理人员、监管事务专家和供应链高阶主管进行专家访谈，以了解相关人员对临床效用、处方趋势、监管限制和营运风险的观点。这些访谈优先考虑直接参与镇痛药选择、采购和患者管理的从业人员和决策者，从而确保研究结果基于真实的临床实践。

一份简洁的总结，整合了临床趋势、监管考虑、供应链挑战和细分市场优先事项，以指南策略规划。

总而言之，镇痛药产业目前正经历重大变革，其驱动力包括临床变革时期转向多元化疼痛管理、监管机构对安全性和预防滥用问题的重视，以及证明药物实际价值的商业性压力。这些趋势既为生产商和经销商带来了挑战，也带来了机会。挑战包括应对贸易政策和监管复杂性对供应链的影响，而机会则体现在差异化製剂、替代给药系统以及能够改善治疗效果和提高用药依从性的整合数位化支持等领域。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：按药物类型分類的镇痛药市场

  • 非阿片类药物
    • 乙酰胺酚
    • 非类固醇消炎剂
    • 水杨酸
  • 阿片类药物
    • 可待因
    • Fentanyl
    • 氢可酮
    • 氢可酮
    • 羟考酮

第九章：止痛药市场：依给药途径划分

  • 肌肉内部
  • 静脉注射（IV）
  • 口服
    • 胶囊
    • 药片
  • 直肠
  • 外用
  • 经皮

第十章：镇痛药市场：依适应症划分

  • 急性疼痛
    • 与创伤相关的疼痛
    • 术后疼痛
  • 慢性疼痛
    • 关节炎
    • 腰痛
    • 癌症疼痛
    • 神经性疼痛

第十一章 镇​​痛药市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十二章：止痛药市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 止痛药市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 镇痛药市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国止痛药市场

第十六章：中国止痛药市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Bayer AG
  • Bristol-Myers Squibb Company
  • CH Boehringer Sohn AG & Co. KG
  • Cipla Limited
  • CSPC Pharmaceutical Group
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Grunenthal GmbH
  • Haleon plc
  • Hikma Pharmaceuticals plc
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Mallinckrodt plc
  • Merck KGaA
  • Novartis AG
  • Perrigo Company plc
  • Pfizer Inc.
  • Reckitt Benckiser Group plc
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-434CCDA05184

The Analgesics Market was valued at USD 44.96 billion in 2025 and is projected to grow to USD 47.99 billion in 2026, with a CAGR of 7.04%, reaching USD 72.43 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 44.96 billion
Estimated Year [2026] USD 47.99 billion
Forecast Year [2032] USD 72.43 billion
CAGR (%) 7.04%

A concise introduction to the evolving analgesics ecosystem highlighting clinical demand, regulatory pressures, and innovation drivers shaping stakeholder strategies

The analgesics landscape sits at the intersection of clinical need, regulatory scrutiny, and rapid therapeutic innovation. Patients and clinicians demand effective, safe, and accessible pain management options across acute and chronic conditions, while manufacturers face pressing challenges related to opioid stewardship, formulation innovation, and supply chain resilience. Against this backdrop, public policy debates and emerging delivery technologies are reshaping how analgesics are developed, distributed, and adopted.

Recent years have seen a shift from one-size-fits-all prescribing towards more nuanced, patient-centric approaches that weigh efficacy, safety, and abuse potential. This dynamic is motivating new product development in both non-opioid and opioid categories, as well as renewed interest in alternative routes of administration that can improve adherence and reduce systemic exposure. Simultaneously, payers and health systems are scrutinizing real-world outcomes and cost-effectiveness more closely, which is influencing formulary decisions and adoption timelines.

As a result, stakeholders across the value chain-manufacturers, clinicians, distributors, and regulators-must balance short-term operational imperatives with longer-term strategic planning. This introductory perspective frames the subsequent sections, offering a lens through which to interpret technological, regulatory, and commercial developments that will influence product life cycles and patient outcomes in the near to medium term.

A forward-looking synthesis of clinical, technological, and regulatory shifts that are redefining development pathways, prescribing behavior, and distribution strategies

The analgesics landscape is undergoing transformative shifts driven by converging clinical, technological, and policy forces. Clinically, the emphasis on multimodal pain management has elevated non-opioid therapies and adjunctive strategies, reducing reliance on high-dose opioid prescribing while creating opportunities for differentiated formulations that target specific pain types. Technological advances in formulation science, including controlled-release matrices and transdermal platforms, are expanding therapeutic options and enabling more precise dosing regimens.

On the regulatory front, heightened vigilance around opioid-related harms continues to influence labeling, prescribing guidelines, and post-market surveillance requirements. This has prompted manufacturers to innovate not only at the molecular level but also in risk-mitigation strategies, such as abuse-deterrent formulations and integrated patient education programs. Meanwhile, digital health tools are beginning to integrate with analgesic care pathways, offering remote monitoring, adherence support, and real-world data capture that can inform clinical decision-making and payer negotiations.

Commercially, distribution and access models are evolving as healthcare purchasers prioritize value-based outcomes. Retail, hospital, and online pharmacy channels are each adapting to new consumer expectations and regulatory requirements. These shifts are creating a more complex competitive landscape where agility in regulatory compliance, supply chain management, and evidence generation confers a strategic advantage. Taken together, these transformative dynamics are redefining how analgesic therapies are developed, evaluated, and delivered to patients.

An evidence-based analysis of how United States tariff measures through 2025 could reshape supply chains, sourcing strategies, and operational resilience across the analgesics value chain

The cumulative effects of trade policy decisions, including tariff actions instituted by the United States through 2025, are adding a new layer of complexity to analgesics supply chains and manufacturing economics. Tariff measures affecting raw materials, active pharmaceutical ingredients, and finished goods can increase procurement costs for manufacturers and contract manufacturers that rely on global supplier networks. In response, firms are reevaluating sourcing strategies, nearshoring certain inputs, and negotiating longer-term supplier agreements to stabilize input costs and minimize production disruptions.

These adjustments carry operational implications that extend beyond procurement. Manufacturers may need to revisit production scheduling, inventory buffers, and contractual terms with distributors to absorb or pass through incremental cost pressures while maintaining compliance with pricing transparency and reimbursement rules. Additionally, increased input costs can influence decisions regarding formulation selection and packaging, prompting a reassessment of cost-to-serve across different routes of administration and product formats.

Beyond direct cost impacts, tariff-driven supply chain shifts have strategic ramifications for market access and competitiveness. Companies with diversified manufacturing footprints and vertically integrated supply chains are better positioned to manage tariff-related volatility, while smaller players and those with concentrated sourcing may face heightened operational risk. In light of these challenges, stakeholders should apply scenario planning to identify critical supply nodes, stress-test supplier alternatives, and prioritize investments that enhance supply chain visibility and agility. By anticipating tariff-induced disruptions and implementing pragmatic mitigation measures, organizations can preserve continuity of care and support resilient access to analgesic therapies.

A detailed segmentation-driven perspective connecting drug classes, delivery routes, clinical indications, and distribution pathways to guide product design and channel strategies

Segmentation insights reveal where clinical demand intersects with commercial opportunity, and a granular view of product, delivery, indication, and distribution dynamics helps clarify priorities for innovation and investment. Based on type of drug, the market divides into non-opioids and opioids; non-opioids encompass acetaminophen, non-steroidal anti-inflammatory drugs, and salicylates, while opioids are further segmented into codeine, fentanyl, hydrocodone, morphine, and oxycodone, each with distinct clinical use profiles and regulatory considerations. Based on route of administration, the landscape includes intramuscular, intravenous, oral, rectal, topical, and transdermal delivery options, with oral formats further differentiated into capsules and tablets, and each route implicating different formulation challenges and patient adherence patterns.

Based on indication, pain management needs are categorized into acute and chronic pain; acute pain includes injury-related and postoperative pain where rapid onset and predictable duration are priorities, while chronic pain covers conditions such as arthritis, back pain, cancer pain, and neuropathic pain where long-term safety, tolerability, and functional outcomes matter most. Based on distribution channel, access is governed by hospital pharmacies, online pharmacies, and retail pharmacies, each channel imposing different requirements around inventory management, patient counseling, regulatory compliance, and reimbursement procedures.

Taken together, these segmentation dimensions highlight areas for targeted development. For example, formulations tailored to chronic neuropathic pain may prioritize sustained-release oral or transdermal delivery and require robust tolerability data, while postoperative care solutions emphasize rapid-onset IV or intramuscular products alongside clear protocols for tapering. Channel strategies must align with patient touchpoints: hospital pharmacies are critical for inpatient and perioperative management, retail pharmacies for community access and chronic therapy continuity, and online pharmacies for convenience and adherence support. Integrating these segment-level insights supports product design choices, evidence strategies, and go-to-market planning that reflect real-world clinical use and distribution realities.

A regionalized appraisal of regulatory diversity, payer priorities, and distribution complexities across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape access and adoption

Regional dynamics influence demand patterns, regulatory expectations, and distribution priorities, with distinct implications across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, healthcare systems and payer structures emphasize both acute care efficiency and outpatient chronic pain management, with strong attention to opioid stewardship that shapes prescribing behavior and formulary placement. Regulatory and reimbursement environments in the Americas often incentivize evidence generation focused on real-world effectiveness and safety, which affects clinical adoption and procurement decisions.

In Europe, Middle East & Africa, regulatory frameworks vary considerably across jurisdictions, driving the need for localized regulatory strategies and region-specific clinical evidence. Access pathways and distribution models are heterogeneous, ranging from highly centralized national health systems to fragmented private markets, which requires tailored approaches to pricing, reimbursement dossiers, and supply chain logistics. The Asia-Pacific region presents a diverse set of market conditions where rapid urbanization, expanding healthcare infrastructure, and growing demand for patient-centric therapies are accelerating uptake of novel formulations and alternative delivery systems. However, regulatory harmonization is uneven across the region, necessitating strategic sequencing of country launches and adaptive regulatory engagement.

Across all regions, differences in healthcare financing, physician prescribing norms, and patient expectations mean that global product strategies must be adaptable. Manufacturers should align clinical development plans, pharmacovigilance activities, and distribution partnerships with regional priorities to optimize adoption and ensure consistent supply while respecting local regulatory and cultural contexts. This regionalized approach supports more effective resource allocation and mitigates the risk of one-size-fits-all strategies in a geographically diverse global market.

A competitive analysis emphasizing evidence-driven differentiation, strategic partnerships, and supply chain agility as determinants of long-term success in analgesics

Competitive dynamics in analgesics are shaped by a mix of established pharmaceutical companies, specialty manufacturers, and emerging innovators focused on formulation and delivery technologies. Market leaders tend to compete on the basis of clinical evidence, safety profiles, and supply chain reliability, while newer entrants differentiate through novel delivery platforms, abuse-deterrent features, and targeted indication strategies. Partnerships between biopharmaceutical firms and technology providers are becoming more common, enabling the integration of digital health components that support adherence and real-world evidence collection.

Intellectual property strategies remain important where novel molecules or distinctive delivery systems are involved, but competitive positioning increasingly depends on demonstrating real-world benefit and operational excellence across the supply chain. Strategic alliances with contract development and manufacturing organizations, distribution partners, and specialty pharmacies can accelerate market entry and expand reach without necessitating full vertical integration. At the same time, vigilance around pharmacovigilance and regulatory compliance is essential to maintaining trust with prescribers and patients, particularly for opioid therapies.

Going forward, companies that combine robust clinical evidence packages with agile manufacturing footprints and patient-centric service models will be best positioned to capture clinical uptake and sustain long-term relationships with healthcare systems. This requires a coordinated approach that aligns R&D, regulatory, commercial, and supply chain functions to deliver reliable products and measurable outcomes across diverse care settings.

Actionable recommendations for executives to align product innovation, supply chain resilience, evidence generation, and partnerships with evolving clinical and regulatory priorities

Industry leaders should prioritize strategic moves that align product development with clinical practice, regulatory expectations, and resilient supply chain design to maintain competitive advantage. First, investing in abuse-deterrent and patient-centric formulations can address both clinical needs and regulatory scrutiny; focusing development on delivery systems that reduce misuse risk while preserving analgesic efficacy will resonate with prescribers and payers. Second, strengthening supply chain resilience through supplier diversification, nearshoring of critical inputs, and enhanced inventory visibility will mitigate exposure to trade policy shifts and unexpected disruptions.

Third, generating high-quality real-world evidence and health economics data will support reimbursement negotiations and demonstrate value to payers and healthcare systems. Integrating digital tools for adherence monitoring and outcome tracking can augment evidence generation and provide differentiating post-market data. Fourth, tailoring regional launch strategies to local regulatory and payer environments will improve uptake; sequencing launches and adapting promotional messaging to regional clinical norms and distribution channel requirements will optimize resource allocation.

Finally, cultivating strategic partnerships across the ecosystem-from contract manufacturers to specialty pharmacies and digital health vendors-can accelerate commercialization while controlling cost and complexity. By combining these actions, companies can better navigate regulatory pressures, supply chain volatility, and shifting clinical expectations, thereby enhancing the likelihood of sustained adoption and improved patient outcomes.

A transparent and methodical research approach combining expert interviews, literature synthesis, and iterative validation to underpin credible, decision-ready insights

This research employed a multi-method approach combining primary qualitative interviews, secondary literature synthesis, and structured data validation to ensure robust and actionable insights. Primary research involved expert interviews with clinicians, formulary managers, regulatory affairs professionals, and supply chain executives to capture stakeholder perspectives on clinical utility, prescribing trends, regulatory constraints, and operational risks. These conversations prioritized practitioners and decision-makers directly involved in analgesic selection, procurement, and patient management to ground findings in real-world practice.

Secondary research drew on peer-reviewed clinical literature, regulatory guidance documents, and publicly available policy analyses to contextualize trends in analgesic use, safety considerations, and formulation innovations. Where appropriate, regulatory approvals, labeling changes, and guideline updates were reviewed to establish a defensible baseline for analysis. Data triangulation techniques were applied to reconcile differing information sources and to identify consistent patterns that informed segmentation and regional assessments.

Finally, findings were validated through iterative reviews with domain experts and cross-functional stakeholders to confirm interpretability and practical relevance. Limitations were acknowledged explicitly, including the evolving nature of regulatory frameworks and the potential for future policy changes to influence dynamics. This methodological rigor supports the credibility of the conclusions and recommendations presented, while also enabling readers to gauge the applicability of insights to their own strategic contexts.

A concise concluding synthesis that integrates clinical trends, regulatory considerations, supply chain imperatives, and segmentation priorities to guide strategic planning

In summary, the analgesics sector is navigating a period of substantive change driven by clinical shifts toward multimodal pain management, regulatory emphasis on safety and misuse prevention, and commercial pressures that reward evidence of real-world value. These dynamics create both challenges and opportunities for manufacturers and distributors: challenges include managing supply chain exposure to trade policy and regulatory complexity, while opportunities lie in differentiated formulations, alternative delivery systems, and integrated digital support that can improve outcomes and adherence.

Strategically, success will hinge on the ability to align product innovation with payer and prescriber expectations, to build resilient supply chains that absorb policy-induced volatility, and to generate the evidence that convinces healthcare purchasers of clinical and economic value. Regional nuances require tailored approaches to regulatory engagement and market access, and segmentation insights should inform product design choices that match clinical needs with patient preferences and channel realities. By executing on these priorities, organizations can contribute to safer, more effective, and more accessible pain management solutions while protecting commercial performance.

The collective implication is clear: a coordinated, evidence-driven, and regionally sensitive strategy will be essential to navigate near-term disruptions and to position analgesic therapies for long-term relevance in an increasingly outcome-focused healthcare environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Analgesics Market, by Type of Drug

  • 8.1. Non-Opioids
    • 8.1.1. Acetaminophen
    • 8.1.2. Non-Steroidal Anti-Inflammatory Drugs
    • 8.1.3. Salicylates
  • 8.2. Opioids
    • 8.2.1. Codeine
    • 8.2.2. Fentanyl
    • 8.2.3. Hydrocodone
    • 8.2.4. Morphine
    • 8.2.5. Oxycodone

9. Analgesics Market, by Route of Administration

  • 9.1. Intramuscular
  • 9.2. Intravenous (IV)
  • 9.3. Oral
    • 9.3.1. Capsules
    • 9.3.2. Tablets
  • 9.4. Rectal
  • 9.5. Topical
  • 9.6. Transdermal

10. Analgesics Market, by Indication

  • 10.1. Acute Pain
    • 10.1.1. Injury-related pain
    • 10.1.2. Postoperative pain
  • 10.2. Chronic Pain
    • 10.2.1. Arthritis
    • 10.2.2. Back pain
    • 10.2.3. Cancer pain
    • 10.2.4. Neuropathic pain

11. Analgesics Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Analgesics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Analgesics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Analgesics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Analgesics Market

16. China Analgesics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Bayer AG
  • 17.7. Bristol-Myers Squibb Company
  • 17.8. C.H. Boehringer Sohn AG & Co. KG
  • 17.9. Cipla Limited
  • 17.10. CSPC Pharmaceutical Group
  • 17.11. Dr. Reddy's Laboratories Ltd.
  • 17.12. Eli Lilly and Company
  • 17.13. GlaxoSmithKline plc
  • 17.14. Grunenthal GmbH
  • 17.15. Haleon plc
  • 17.16. Hikma Pharmaceuticals plc
  • 17.17. Johnson & Johnson Services, Inc.
  • 17.18. Lupin Limited
  • 17.19. Mallinckrodt plc
  • 17.20. Merck KGaA
  • 17.21. Novartis AG
  • 17.22. Perrigo Company plc
  • 17.23. Pfizer Inc.
  • 17.24. Reckitt Benckiser Group plc
  • 17.25. Sanofi S.A.
  • 17.26. Sun Pharmaceutical Industries Limited
  • 17.27. Teva Pharmaceutical Industries Ltd.
  • 17.28. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANALGESICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANALGESICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANALGESICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANALGESICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANALGESICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANALGESICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANALGESICS MARKET SIZE, BY NON-OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANALGESICS MARKET SIZE, BY NON-OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANALGESICS MARKET SIZE, BY NON-OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANALGESICS MARKET SIZE, BY ACETAMINOPHEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANALGESICS MARKET SIZE, BY ACETAMINOPHEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANALGESICS MARKET SIZE, BY ACETAMINOPHEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANALGESICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANALGESICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANALGESICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANALGESICS MARKET SIZE, BY SALICYLATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANALGESICS MARKET SIZE, BY SALICYLATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANALGESICS MARKET SIZE, BY SALICYLATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANALGESICS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANALGESICS MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANALGESICS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANALGESICS MARKET SIZE, BY CODEINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANALGESICS MARKET SIZE, BY CODEINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANALGESICS MARKET SIZE, BY CODEINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANALGESICS MARKET SIZE, BY FENTANYL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANALGESICS MARKET SIZE, BY FENTANYL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANALGESICS MARKET SIZE, BY FENTANYL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANALGESICS MARKET SIZE, BY HYDROCODONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANALGESICS MARKET SIZE, BY HYDROCODONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANALGESICS MARKET SIZE, BY HYDROCODONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANALGESICS MARKET SIZE, BY MORPHINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANALGESICS MARKET SIZE, BY MORPHINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANALGESICS MARKET SIZE, BY MORPHINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANALGESICS MARKET SIZE, BY OXYCODONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANALGESICS MARKET SIZE, BY OXYCODONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANALGESICS MARKET SIZE, BY OXYCODONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANALGESICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANALGESICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANALGESICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANALGESICS MARKET SIZE, BY INTRAVENOUS (IV), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANALGESICS MARKET SIZE, BY INTRAVENOUS (IV), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANALGESICS MARKET SIZE, BY INTRAVENOUS (IV), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANALGESICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANALGESICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANALGESICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANALGESICS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANALGESICS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANALGESICS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANALGESICS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANALGESICS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANALGESICS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANALGESICS MARKET SIZE, BY RECTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANALGESICS MARKET SIZE, BY RECTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANALGESICS MARKET SIZE, BY RECTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANALGESICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANALGESICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANALGESICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANALGESICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANALGESICS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANALGESICS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANALGESICS MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANALGESICS MARKET SIZE, BY ACUTE PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANALGESICS MARKET SIZE, BY ACUTE PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANALGESICS MARKET SIZE, BY INJURY-RELATED PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANALGESICS MARKET SIZE, BY INJURY-RELATED PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANALGESICS MARKET SIZE, BY INJURY-RELATED PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANALGESICS MARKET SIZE, BY POSTOPERATIVE PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANALGESICS MARKET SIZE, BY POSTOPERATIVE PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANALGESICS MARKET SIZE, BY POSTOPERATIVE PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANALGESICS MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANALGESICS MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANALGESICS MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANALGESICS MARKET SIZE, BY ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANALGESICS MARKET SIZE, BY ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANALGESICS MARKET SIZE, BY ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANALGESICS MARKET SIZE, BY BACK PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANALGESICS MARKET SIZE, BY BACK PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANALGESICS MARKET SIZE, BY BACK PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANALGESICS MARKET SIZE, BY CANCER PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANALGESICS MARKET SIZE, BY CANCER PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANALGESICS MARKET SIZE, BY CANCER PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANALGESICS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANALGESICS MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANALGESICS MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANALGESICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANALGESICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANALGESICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANALGESICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANALGESICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANALGESICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANALGESICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANALGESICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANALGESICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANALGESICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS ANALGESICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL ANALGESICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. GCC ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. GCC ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 192. GCC ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 193. GCC ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 194. GCC ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. GCC ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 196. GCC ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 197. GCC ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 198. GCC ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 199. GCC ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. G7 ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. G7 ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 222. G7 ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 223. G7 ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 224. G7 ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. G7 ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 226. G7 ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 227. G7 ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 228. G7 ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 229. G7 ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. NATO ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. NATO ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 232. NATO ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 233. NATO ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 234. NATO ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. NATO ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 236. NATO ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 237. NATO ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 238. NATO ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 239. NATO ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA ANALGESICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA ANALGESICS MARKET SIZE, BY TYPE OF DRUG, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA ANALGESICS MARKET SIZE, BY NON-OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA ANALGESICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA ANALGESICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA ANALGESICS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA ANALGESICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA ANALGESICS MARKET SIZE, BY ACUTE PAIN, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA ANALGESICS MARKET SIZE, BY CHRONIC PAIN, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA ANALGESICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)